HER2-family signalling mechanisms, clinical implications and targeting in breast cancer

Approximately 20 % of human breast cancers (BC) overexpress HER2 protein, and HER2-positivity is associated with a worse prognosis. Although HER2-targeted therapies have significantly improved outcomes for HER2-positive BC patients, resistance to trastuzumab-based therapy remains a clinical problem....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2015-01, Vol.149 (1), p.5-15
Hauptverfasser:	Elster, N., Collins, D. M., Toomey, S., Crown, J., Eustace, A. J., Hennessy, B. T.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Cancer research Cancer therapies Drug resistance Drug Resistance, Neoplasm - genetics Epidermal growth factor Female Humans Medicine Medicine & Public Health Oncology Phosphatidylinositol 3-Kinases - genetics Prognosis Receptor, ErbB-2 - genetics Review Signal Transduction - drug effects Trastuzumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!